CYP-002

CYP-002 is an allogeneic cell therapy consisting of mesenchymal stromal cells (MSCs) derived from induced pluripotent stem cells (iPSCs), developed by Cynata Therapeutics using its proprietary Cymerus platform. The manufacturing process utilizes a non-integrating synthetic mRNA reprogramming strategy to generate iPSCs from adult skin fibroblasts, which are then differentiated into a highly consistent and scalable population of induced MSCs (iMSCs). Unlike traditional bone marrow-derived MSCs, CYP-002 exhibits superior proliferative potential (exceeding 70 doublings) and high homogeneity. In preclinical studies, these iMSCs have demonstrated the ability to support the hematopoietic niche by secreting high levels of trophic and pro-angiogenic factors such as SDF-1 (CXCL12), VEGF-A, MCP-1 (CCL2), LIF, and TWEAK. These factors facilitate the engraftment of CD34+ hematopoietic progenitor cells and accelerate the recovery of white blood cells, platelets, and hemoglobin following myeloablative conditioning or irradiation. CYP-002 is primarily being clinically evaluated for the treatment of critical limb ischemia (CLI), leveraging its ability to promote angiogenesis and tissue repair, and has shown a favorable safety profile without evidence of sarcoma formation or ectopic tissue development in animal models.

Other names

Cymerus iMSCsiPSC-derived mesenchymal stromal cellsinduced mesenchymal stromal cells